Best GLP-1 Providers in Wyoming (2026)

See by medication

Looking for a specific GLP-1? Browse Wyoming providers by drug.

About GLP-1s in Wyoming

Wyoming allows telehealth GLP-1 prescriptions, which is critical given the state's vast rural geography. Wyoming Medicaid covers GLP-1s only for type 2 diabetes.

• •Wyoming's adult obesity rate is 30.7%
• •Telehealth is essential for Wyoming's rural communities
• •Wyoming Medicaid limits GLP-1 coverage to diabetes

Top Cities for GLP-1 Treatment in Wyoming

Telehealth providers ship to all Wyoming addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Wyoming GLP-1 clinic directory →

GLP-1 Care Access in Wyoming: The Numbers

Wyoming has 57 NPI-registered in-person weight-management clinics across 15 cities — 3 with an obesity-medicine taxonomy, 11 endocrinology, and 43 bariatric — alongside 97 telehealth programs that ship to Wyoming addresses. The cheapest verified ongoing compounded semaglutide price available to Wyoming residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Wyoming

In Q1 2026, Wyoming Medicaid reimbursed approximately $1,621,807 across 1,556 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Wyoming cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $209/mo.

For the exact criteria, drug list, and appeal process, read our Wyoming Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Wyoming

According to CDC data, 30.7% of Wyoming adults have obesity (BMI of 30 or higher). This places Wyoming at #30 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Wyoming residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions